XML 29 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Description of Business and Basis of Presentation - Additional Information (Detail)
 0 Months Ended 9 Months Ended 283 Months Ended 0 Months Ended 3 Months Ended 0 Months Ended 9 Months Ended 0 Months Ended 9 Months Ended
Jul. 18, 2014
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2013
USD ($)
Sep. 30, 2014
USD ($)
Jul. 31, 2014
EUR (€)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Aug. 11, 2014
License and Collaboration Agreement with Sanofi
Sep. 30, 2014
License and Collaboration Agreement with Sanofi
USD ($)
Sep. 23, 2014
License and Collaboration Agreement with Sanofi
USD ($)
Aug. 11, 2014
License and Collaboration Agreement with Sanofi
USD ($)
Aug. 11, 2014
License and Collaboration Agreement with Sanofi
Second Amendment Facility Agreement
USD ($)
Aug. 11, 2014
License and Collaboration Agreement with Sanofi
Sanofi-Aventis Deutschland GmbH
Sep. 30, 2014
Maximum
ATM Agreements
USD ($)
Sep. 30, 2014
Senior convertible notes due August 15, 2015
USD ($)
Dec. 31, 2013
Senior convertible notes due August 15, 2015
USD ($)
Aug. 18, 2010
Senior convertible notes due August 15, 2015
USD ($)
Feb. 28, 2014
Senior convertible notes due December 31, 2019
Deerfield
Tranche B notes
Sep. 30, 2014
Senior convertible notes due December 31, 2019
Deerfield
Tranche B notes
USD ($)
Sep. 23, 2014
Senior convertible notes due December 31, 2019
Deerfield
Tranche B notes
USD ($)
Feb. 28, 2014
Senior convertible notes due December 31, 2019
Deerfield
Tranche B notes
USD ($)
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                                          
Deficit accumulated during the development stage   $ 2,458,343,000   $ 2,458,343,000   $ 2,296,402,000                              
Goodwill impairment       151,428,000                                  
Cash flow from operation since inception       1,700,000,000                                  
Cash and cash equivalents   172,465,000 93,803,000 172,465,000   70,790,000 61,840,000                            
Debt facility principal amount                             100,000,000 100,000,000 100,000,000       90,000,000
Senior notes, effective interest rate                   8.50%         5.75%   5.75%     8.75% 9.75%
Debt instrument maturity date                             Aug. 15, 2015     Dec. 31, 2019      
Available borrowings under loan agreement   30,100,000   30,100,000                                  
Potential proceeds from the exercise of warrants from February 2012 public offering   20,000,000   20,000,000                                  
Offering price of common stock under agreement                           50,000,000              
Additional sales of notes   40,000,000 79,500,000 159,500,000                             70,000,000    
Up-front fee                 150,000,000                        
Potential milestone payment                     775,000,000                    
Profits and losses sharing percentage               35.00%         65.00%                
Maximum secured loan facility                   175,000,000   175,000,000               175,000,000  
Prepaid expenses and other current assets   20,253,000   20,253,000   5,485,000                              
Prepayment of prepaid insurance, and prepaid clinical trial expenses   15,000,000   15,000,000                                  
Remaining minimum amount committed in calendar years 2015 through 2019         120,100,000                                
Supply Agreement expiration period Dec. 31, 2019                                        
Supply Agreement renewal period 2 years                                        
Consideration received 9,300,000                                        
Offset expense associated with intellectual property $ 1,400,000